The COVID vaccine given by nasal spray from Instituto do Coração (Incor) has not been published and is intended as an option for a booster dose. After the good results with mice, it’s time to test in humans. The implementation of the first two phases of clinical studies depends on the approval of documents submitted to the National Health Control Agency (Anvisa) on Thursday. The research coordinator, Jorge Elias Khalil Filho, believes that tests should begin in January next year, only with patients already immunized.

In a vaccination progress scenario, Kleil assesses that a nasal immunizing agent will be “successful,” because if it proves effective at the end of clinical stages, the prediction is that it will attack the transmission of the coronavirus. . “The big problem with current vaccines is that they prevent serious disease, but the patient can still get infected and transmit it. We want to avoid infection in the nose, we got it right from the start,” explains the head of the hospital’s Clinical Immunology and Allergy Laboratory from the University of São Paulo Clinics. (USP) and Professor at the University of the South Pacific School of Medicine.

Another advantage of the fortifying agent is that, according to Kellel, with some adjustments by the national industry, it will be possible to produce the active medicinal ingredient (IFA) of the fortifying agent in Brazil. With the adoption and management of immunization agents so far, the country is dependent on importing IFAs, which has delayed the arrival and production of vaccines. “The animals’ response has been fantastic,” Khalil says of the preclinical study. Experiments with mice, according to the researcher, resulted in high levels of anti-memory (IgG) and mucosal (IgA) antibodies, as well as a good protective cellular response.